跳至主要内容
临床试验/NCT03062839
NCT03062839Unknown3 期

Melatonin as Adjuvant Treatment for ADHD in Adults

Hospital Israelita Albert Einstein1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2017年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
120
试验地点
1
主要终点
Adult ADHD Investigator Symptom Rating Scale.

研究概览

简要总结

This study aims to evaluate the effect of melatonin supplementation as adjuvant treatment in ADHD in adults.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female age 18-60 inclusive. Primary diagnosis of ADHD AISRS total score ≥ 24 CGI-S ≥4 (moderately ill or worse). Understands and is able, willing, and likely to fully comply with the study procedures and restrictions.
  • Has given written informed consent to participate in the study.

排除标准

  • BMI less than18.5 or greater than
  • Any underlying/ history or current diagnosis of systemic and/or metabolic disease (e.g. diabetes, Crohn's disease) and/or neurological condition state that may render the subject illegible to participate in the study as assessed by medical history, physical exam, clinical and lab evaluation.
  • History of uncontrolled hypertension or a resting systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg (Subjects with well controlled hypertension on a stable dose (2 months) of anti-hypertensives will be allowed to participate).
  • Major depression or anxiety disorder which is a focus of treatment or requires taking medication.
  • A lifetime history of psychosis or bipolar disorder Has any concurrent chronic or unstable medical condition that could confound with the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
  • Subjects taking any medication with CNS effects Subjects with a history of two or more prior failed adequate trials of ADHD treatment due to adverse events.
  • Use of dietary supplements with potential CNS effect, including omega-3 supplements, 30 days before study initiation and throughout the study.
  • Clinical history of cognitive impairment in judgment of investigator. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed at screening visit prior to randomization. Women of childbearing potential must agree to use adequate birth control for the entire duration of the study.
  • Subjects with a current (within the last 3 months) DSM-V diagnosis of alcohol or drug abuse or dependence (excluding nicotine).
  • Has taken an investigational drug or taken part in a clinical trial within 30 days prior to screening.
  • Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.
  • Previous use of melatonin or melatonin analogues

研究组 & 干预措施

Melatonin

Experimental

Melatonin 5 mg taken 30 minutes before bed time

干预措施: Melatonin 5 mg (Drug)

Placebo

Placebo Comparator

Placebo identical to melatonin capsule taken 30 min before bed time

干预措施: Melatonin 5 mg (Drug)

结局指标

主要结局

Adult ADHD Investigator Symptom Rating Scale.

时间窗: 12 weeks

Each of the individual DSM-IV symptoms of ADHD is rated 0 to 3 on a scale of severity.

次要结局

  • Anxiety(12 weeks)
  • CGI-S / I(12 weeks)
  • Depression(12 weeks)
  • Adverse Event Monitoring(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验